SAN DIEGO, Oct. 27 /PRNewswire/ — BioAtom Inc. (private) announced today that it will present at the 3rd annual BIOCOM Investor Conference on Tuesday, October 28, 2008 at 2:30 PM PDT (5:30 PM EDT) at the Hyatt Regency La Jolla in San Diego, California.
Myron Karasik, M.B.A., C.M.C., Director of Finance, will present an overview of Medical Division of BioAtom Inc. of Costa Mesa, CA, dedicated to development and commercialization of Neutron Cancer Diagnostics. Its ONCOSENSOR(TM), a nanotechnology probe, will undergo in vivo evaluation at Center for Functional Onco Imaging, UC Irvine, in collaboration with Radiation Oncology Group, Long Beach Memorial Hospital.
From Bomb Detector to Cancer Diagnostic Probe. Malignant tumors are chemically different from normal tissue. ONCOSENZOR(TM) can non-invasively detect in vitro chemical differences as small as 1 atom/molecule. Its core technology was developed under US Army contracts for non-intrusive detectors of bioagents and explosives in a previous company (no longer in existence), by co-founders of BioAtom, at a cost to shareholders of over $40 million.
Our mission is to provide an early warning, walk-in, painless (non-invasive) and “instant” (online) cancer diagnosis aid that is a quantum leap ahead of competing firms. Operating in tandem with any one of the imaging probes, we hope to ultimately achieve needle-less biopsy. The method has the potential for forewarning of stroke, Alzheimer, and cardiovascular diseases.
Marketing of ONCOSENZOR(TM) to animal clinics, a $13 Billion/year market, does not require FDA approval.
Anna Radovic, Ph.D., 36, President and Chief Scientific Officer, an international cancer researcher and co-patentee, was first to irradiate DNA by neutrons. Christian Druey, B.E.E., 38, has been instrumental in commercialization of medical imaging and explosive detection devices. Bogdan Maglich, Ph.D., CTO and Chairman, the inventor of the core technology, has been elected one of “50 Champions of Innovation” worldwide.
TV interviews: (1) http://www.bioatominc.com/ (2006); (2) http://www.yourcancertoday.com/, (2007) season 2 episode 7. Company has no general non-NDA website as a matter of proprietary policy.
Safe Harbor Statement
This press release contains certain forward-looking statements and projections which include, but are not limited to, references to BioAtom’s technology, strategy, and ability to commercialize a novel diagnostic aid. Uncertainties and other factors may cause the actual results to materially differ from those predicted. BioAtom does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
BioAtom Inc.
CONTACT: Dr Anna Radovic, President of BioAtom, +1-714-966-2986, cell+1-949-400-1511, [email protected]
Web site: http://www.bioatominc.com/http://www.yourcancertoday.com/
Comments